ABSI's most advanced pipeline member is ABS-101, an anti-TL1A antibody. TL1A is a tumor necrosis factor-like cytokine that activates death domain receptor 3 (DR3) to play a role in mucosal immunity, ...
Management anticipates "initiation of a Phase I/IIa trial [for ABS-201] in early '26 with potential interim efficacy and proof-of-concept data anticipated later that year." Jonasson expects to "sign ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results